Rosen's Breast Pathology, 4e

406

Chapter 11

172. Guidi AJ, Schnitt SJ, Fischer L, et al. Vascular permeability fac- tor (vascular endothelial growth factor) expression and angiogen- esis in patients with ductal carcinoma in situ of the breast. Cancer 1997;80:1945–1953. 173. Carpenter PM, ChenWP, Mendez A, et al. Angiogenesis in the progres- sion of breast ductal proliferations. Int J Surg Pathol 2011;19:335–341. 174. Adler EH, Sunkara JL, Patchefsky AS, et al. Predictors of disease pro- gression in ductal carcinoma in situ of the breast and vascular pat- terns. Hum Pathol 2012;43:550–556. 175. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011;2:232–261. 176. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recom- mendations for immunohistochemical testing of estrogen and proges- terone receptors in breast cancer. J Clin Oncol 2010;28:2784–2795. 177. Lesser ML, Rosen PP, Senie RT, et al. Estrogen and progesterone re- ceptors in breast carcinoma: correlations with epidemiology and pa- thology. Cancer 1981;48:299–309. 178. Barnes R, Masood S. Potential value of hormone receptor assay in car- cinoma in situ of breast. Am J Clin Pathol 1990;94:533–537. 179. Bur ME, Zimarowski MJ, Schnitt SJ, et al. Estrogen receptor im- munohistochemistry in carcinoma in situ of the breast. Cancer 1992;69:1174–1181. 180. Holland PA, Knox WF, Potten CS, et al. Assessment of hormone de- pendence of comedo ductal carcinoma in situ of the breast. J Natl Can- cer Inst 1997;89:1059–1065. 181. Roka S, Rudas M, Taucher S, et al. High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 2004;30:243–247. 182. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen re- ceptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 2005;18:615–620. 183. Allred DC, Carlson RW, Berry DA, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Cancer Netw 2009;7(Suppl. 6):S1–S21. 184. Cohen DA, Dabbs DJ, Cooper KL, et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol 2012;138:796–802. 185. Walker RA, Hanby A, Pinder SE, et al. Current issues in diagnostic breast pathology. J Clin Pathol 2012;65:771–785. 186. Baqai T, Shousha S. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast. Histopathology 2003;42:440–447. 187. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical dem- onstration of c-erbB-2 protein in mammary ductal carcinoma in situ . Hum Pathol 1990;21:1164–1167. 188. Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer 1988;42:842–845. 189. Poller DN, Silverstein MJ, Galea M, et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classifica- tion association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994;7:257–262. 190. Schimmelpenning H, Eriksson ET, Pallis L, et al. Immunohistochemi- cal c-erbB-2 proto-oncogene expression and nuclear DNA content in human mammary carcinoma in situ . Am J Clin Pathol 1992;97(Suppl. 1):S48–S52. 191. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpres- sion in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239–1245. 192. Liu E, Thor A, He M, et al. The HER2 (c-erbB-2) oncogene is fre- quently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027–1032. 193. Ho GH, Calvano JE, Bisogna M, et al. In microdissected ductal car- cinoma in situ , HER2/neu amplification but not p53 mutation is as- sociated with comedo and high grade ductal carcinoma in situ . Cancer 2000;89:2153–2160. 194. Barnes DM, Meyer JS, Gonzalez JG, et al. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ . Breast Cancer Res Treat 1991;18:11–17. 195. Albonico G, Querzoli P, Ferretti S, et al. Biological heterogeneity of breast carcinoma in situ . Ann NY Acad Sci 1996;784:458–461.

196. De Potter CR, Foschini MP, Schelfhout A-M,et al. Immunohisto- chemical study of neu protein overexpression in clinging in situ duct carcinoma of the breast. Virchows Arch [A] 1993;422:375–380. 197. Sek P, Zawrocki A, Biernat W, et al. HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemi- cal study. Histopathology 2010;57:564–571. 198. Rudas M, Neumayer R, Gnant MFX, et al. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 1997;33:39–44. 199. Isola JJ, Holli K, Oksa H, et al. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive dis- ease course in patients with breast cancer. Cancer 1994;73:652–658. 200. Esteva-Lorenzo FJ, Paik S, Harris LN. Serum erbB-2 in ductal carci- noma in situ of the breast—a marker of microinvasion. Acta Oncol 1997;36:651–652. 201. Volas GH, Leitzel K, Teramoto Y, et al. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 1996;78:267–272. 202. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of ductal carcinoma in situ . Hum Pathol 2007;38:197–204. 203. Thike AA, Iqbal J, Cheok PY, et al. Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor– product relationship. J Clin Pathol 2013;66:665–670. 204. O’Malley FP, Vnencak-Jones CL, Dupont WD, et al. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Im- munohistochemical and sequencing data. Lab Invest 1994;71:67–72. 205. Rajan PB, Scott DJ, Perry RH, et al. p53 protein expression in duc- tal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 1997;42:283–290. 206. Poller DN, Bell RJA, Elston CW, et al. p53 protein expression in mam- mary ductal carcinoma in situ : relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993;24:463–468. 207. Leal CB, Schmitt FC, Bento MJ, et al. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and c-erbB-2 protein. Cancer 1995;75:2123–2131. 208. Done SJ, Arneson NCR, Ozcelik H, et al. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasia. Cancer Res 1998;58:785–789. 209. Walker RA, Dearing SJ, Lane DP, et al. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 1991;165:203–211. 210. Barnes R, Masood S, Barker E, et al. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 1991;139:245–250. 211. Simpson JF, O’Malley F, Dupont WD, et al. Heterogeneous expres- sion of nm23 gene product in noninvasive breast carcinoma. Cancer 1994;73:2352–2358. 212. Vos CB, Cleton-Jansen AM, Berx G, et al. E-Cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigen- esis. Br J Cancer 1997;76:1131–1133. 213. Gupta SK, Douglas-Jones AG, Jasani B, et al. E-Cadherin (E-cad) ex- pression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch 1997;430:23–28. 214. Bankfalvi A, Terpe HJ, Breukelmann D, et al. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999;34:25–34. 215. Aasmundstad TA, Haugen OA. DNA ploidy in intraductal breast car- cinomas. Eur J Cancer 1990;26:956–959. 216. Crissman JD, Visscher DW, Kubus J. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast. Arch Pathol Lab Med 1990;114:1239–1253. 217. Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast. A comparison with histologic features. Cancer 1991;68:2602–2607. 218. Locker AP, Horrocks C, Gilmour AS, et al. Flow cytometric and his- tological analysis of ductal carcinoma in situ of the breast. Br J Surg 1990;77:564–567. 219. Pallis L, Skoog L, Falkmer U, et al. The DNA profile of breast cancer in situ . Eur J Surg Oncol 1992;18:108–111. 220. Sataloff DM, Russin Vl, Sohn M, et al. DNA flow cytometric analysis in ductal carcinoma in situ of the breast. Breast Dis 1993;6:195–205. 221. MeyerJE,KopansDB,StomperPC,etal.Occultbreastabnormalities:per- cutaneous preoperative needle localization. Radiology 1984;150:335–337.